Letrozole

Letrozole is a synthetic, nonsteroidal aromatase inhibitor with the molecular formula C17H11N5. Its structure centers on a triazole ring joined to two benzonitrile groups, an arrangement that lets it bind selectively to the aromatase enzyme; because it lowers estrogen throughout the body, it belongs to the broad family of antiestrogen or endocrine therapies. The compound was developed by Novartis and reached the market under the brand name Femara ^[1].

The molecule was patented in 1986 and cleared by United States regulators in 1996. It went on to become one of the more commonly dispensed hormonal medicines and is included on the World Health Organization's Model List of Essential Medicines. In postmenopausal women, the large BIG 1-98 trial found that five years of letrozole reduced breast-cancer recurrence and improved survival when compared with tamoxifen, which helped establish it as a standard adjuvant treatment for early, hormone-sensitive disease ^[1].

Beyond oncology, letrozole has become a leading option for ovulation induction. A landmark multicenter trial reported that women with polycystic ovary syndrome who took letrozole reached higher rates of ovulation and live birth than those given clomiphene, and many fertility guidelines now list it as a first-line choice ^[2]. It has also been examined for male infertility, where reducing estrogen can lift testosterone and support sperm production.

Several further uses are backed by research or clinical practice, though not always by formal approval. Because endometriotic tissue overproduces aromatase, the drug has been trialed to shrink implants and ease the pain of endometriosis ^[3]. It is likewise used to manage gynecomastia, and, when paired with a prostaglandin such as misoprostol, it can improve the effectiveness of medical abortion regimens ^[4]. In pediatric endocrinology it has been studied as a way to delay closure of the growth plates and extend adult height in selected boys.

Letrozole is a prescription-only medicine in the United States, United Kingdom, European Union, and Canada, and it is taken orally as a film-coated tablet. It is contraindicated in premenopausal women outside of supervised fertility care and is avoided during pregnancy. In competitive sport it is banned by the World Anti-Doping Agency, since athletes have misused aromatase inhibitors to blunt the estrogenic side effects of anabolic steroids.

This is a prescription drug. Because it strips out estrogen, common effects mirror menopause: hot flashes, joint and muscle aches, fatigue, headaches, and vaginal dryness. Long-term use in breast cancer speeds bone thinning and raises fracture risk, so bone density is watched and calcium, vitamin D, or bone medicines are often added, and cholesterol can rise. In fertility cycles side effects are usually milder and short lived, though there is a small chance of multiple pregnancy. It must not be used in pregnancy because it can harm a developing baby, and it is not used in women who are still fully premenopausal for cancer treatment without also shutting down ovarian function.

Letrozole is a nonsteroidal aromatase inhibitor metabolized partly through CYP3A4 and undergoes glucuronidation. Letrozole itself acts as a CYP3A4 inhibitor of moderate strength; when combined with abemaciclib, a CDK4/6 inhibitor also metabolized by CYP3A4, both drugs exert combined inhibitory effects on CYP3A4, leading to reduced metabolism of abemaciclib and increased systemic exposure ^[23]. This is a bidirectional pharmacokinetic interaction. Conversely, potent CYP3A4 inducers such as rifampicin and carbamazepine would be expected to reduce letrozole levels, though published clinical studies quantifying this interaction are scarce. The interaction profile of letrozole with most CYP3A4 inhibitors and inducers remains largely undocumented, leaving substantial uncertainty about dose adjustments needed when letrozole is combined with other metabolized agents.

Checking a whole stack? Run it through interactions + stacks.

Letrozole was developed by the pharmaceutical company Ciba-Geigy, later Novatis, as a third-generation nonsteroidal aromatase inhibitor designed to suppress estrogen synthesis with high selectivity. It received US Food and Drug Administration approval in 1997 under the brand name Femara, initially for advanced breast cancer in postmenopausal women whose disease had progressed on antiestrogen therapy, and its indications later expanded to early-stage and extended adjuvant treatment.

In a notable turn, reproductive medicine researchers recognized that the same estrogen suppression could paradoxically stimulate ovulation, and in the early 2000s letrozole began to be studied as an ovulation-inducing agent. A landmark randomized trial later showed higher live-birth rates with letrozole than with clomiphene in women with polycystic ovary syndrome, establishing it as a first-line choice for that indication. It is also used off-label for endometriosis and remains a widely prescribed medicine in oncology and fertility care.

Letrozole holds an excellent reputation across two very different fields, a rare distinction for a single drug. In hormone receptor-positive breast cancer it is a cornerstone endocrine therapy, valued for potently lowering estrogen and slowing tumors that depend on it. In reproductive medicine it has become a preferred agent for ovulation induction in polycystic ovary syndrome, where meta-analyses of randomized trials report higher ovulation, pregnancy, and live-birth rates than the older standard clomiphene, along with a favorable tendency toward single-follicle ovulation.

Its short half-life is an asset for fertility use, clearing quickly and reducing lingering antiestrogenic effects on the uterine lining. As with any aromatase inhibitor, estrogen deprivation can bring side effects such as hot flashes and joint aches. Overall, letrozole is a highly regarded, evidence-rich medicine in both oncology and fertility.